{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-25-000251","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.876339+00:00","generated_at":"2026-05-17T01:27:51.574890+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lilly Q3 revenue up 54% to $17.6B; raises FY2025 guidance on Mounjaro/Zepbound demand","bullets":["Q3 reported EPS $6.21 vs $1.07 YoY; non-GAAP EPS $7.02 vs $1.18.","Revenue $17.6B (up 54% YoY) driven by Mounjaro and Zepbound volume growth.","Raises FY2025 revenue guidance to $63.0-63.5B; reported EPS $21.80-22.50, non-GAAP EPS $23.00-23.70.","Pipeline: plans to submit orforglipron for obesity to global regulators by year-end after positive Phase 3 trials.","U.S. FDA approved Inluriyo (imlunestrant) for advanced/metastatic breast cancer; manufacturing expansions in VA, TX, Puerto Rico."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-25-000251","json":"https://secwatch.observer/filing/0000059478-25-000251.json","markdown":"https://secwatch.observer/filing/0000059478-25-000251.md","text":"https://secwatch.observer/filing/0000059478-25-000251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000251/0000059478-25-000251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000251/lly-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:27:51.574890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}